Uveitis Treatment Global Market Report 2025

The uveitis treatment market size has grown strongly in recent years. It will grow from $1.43 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to several factors, including the increased prevalence of autoimmune conditions, a growing geriatric population, a higher incidence of uveitis, enhanced awareness among healthcare professionals about the importance of early diagnosis and treatment, and a rising occurrence of infectious diseases.

The uveitis treatment market size is expected to see strong growth in the next few years. It will grow to 2.08 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth during the forecast period can be attributed to factors such as the increasing affordability of healthcare services, a rise in age-related eye disorders, a growing senior population, more research initiatives, and heightened awareness of eye health among the public. Key trends in the forecast period include the development of targeted therapies, advancements in laser surgery, innovative drug delivery systems, improvements in ophthalmology diagnostic tools, and a growing adoption of sustained-release drug delivery systems.

The growing prevalence of autoimmune conditions is expected to drive the expansion of the uveitis treatment market. Autoimmune conditions involve diseases in which the immune system attacks and damages the body’s healthy cells, tissues, or organs. The rise in autoimmune diseases is influenced by factors such as genetic predisposition, environmental triggers, and lifestyle changes that affect the immune system. Uveitis treatment helps manage these conditions by reducing inflammation, controlling the immune system's overactivity, and preventing vision loss linked to autoimmune-related eye inflammation. For example, a 2022 report by the Germany-based healthcare data analytics company Versorgungsatlas revealed that, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, leading to a prevalence rate of 8.61%. As a result, the increasing number of autoimmune cases is contributing to the growth of the uveitis treatment market.

Leading companies in the uveitis treatment market are focusing on creating innovative devices such as sustained-release intravitreal implants to improve patient adherence to treatment. These long-acting drug delivery systems are placed in the eye to ensure controlled and prolonged medication release. For instance, in February 2022, Alimera Sciences, a US-based biopharmaceutical company, launched ILUVIEN, a sustained-release intravitreal implant aimed at treating non-infectious posterior uveitis (NIPU) in Spain. The implant delivers fluocinolone acetonide directly into the eye, releasing the drug slowly for up to 36 months. This long-term treatment helps reduce inflammation and prevent relapses in recurrent NIPU. ILUVIEN is the first and only treatment of its kind for this condition, offering a more consistent and long-lasting effect while reducing the frequency of injections and improving patient outcomes.

In September 2024, ANI Pharmaceuticals, a US-based pharmaceutical company, acquired Alimera Sciences for an undisclosed sum. This acquisition aims to enhance ANI’s Rare Disease division and broaden its presence in the ophthalmology market. Alimera Sciences specializes in the development and commercialization of ophthalmic pharmaceuticals, particularly those focused on retinal diseases such as uveitis.

Major players in the uveitis treatment market are Merck & Co. Inc., AbbVie Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Kubota Vision Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Horizon Therapeutics plc, Cipla Ltd., Santen Pharmaceutical Co. Ltd., Galapagos NV, ANI Pharmaceuticals Inc., EyePoint Pharmaceuticals Inc., Entod Pharmaceuticals Ltd., Sirion Therapeutics Inc., Kiora Pharmaceuticals Inc., Lux Biosciences Inc., Inflammasome Therapeutics Inc., and Clearside Biomedical Inc.

North America was the largest region in the uveitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in uveitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the uveitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Uveitis treatment involves medical measures designed to reduce inflammation inside the eye, helping to relieve symptoms and prevent vision loss. The treatment approach depends on the underlying cause and may include corticosteroids, immunosuppressive drugs, or antimicrobial medications. These treatments can be administered in various forms, such as eye drops, oral medications, injections, or implants, depending on the type and severity of the uveitis.

The primary indications for uveitis treatment include anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. Anterior uveitis refers to inflammation of the front part of the uvea, primarily affecting the iris and ciliary body, often resulting in eye pain, redness, and vision changes. Treatment for uveitis can be categorized by the method of administration such as topical, systemic, or injectable therapies. These treatments address either infectious or non-infectious causes. Available therapeutic options include corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungals, and analgesics. These treatments are available through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The uveitis treatment market research report is one of a series of new reports that provides uveitis treatment market statistics, including the uveitis treatment industry global market size, regional shares, competitors with the uveitis treatment market share, detailed uveitis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the uveitis treatment industry. This uveitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The uveitis treatment market consists of sales of drugs, diagnostic tools, surgical equipment, intravitreal implants, and injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.